CORDIS
EU research results

CORDIS

English EN
VERY INNOVATIVE AIDS VACCINE

VERY INNOVATIVE AIDS VACCINE

Objective

The aim of VIAV is to develop a highly innovative Env-based vaccine capable of inducing cross-clade neutralizing antibodies to prevent HIV infection.This represents the most important problem of current Env-based vaccines.VIAV aim will be achieved through new antigen design stemming out from novel virological, immunological and modeling data of the VIAV Consortium indicating that Tat increases HIV cell adsorption, infectivity and tropisms via a molecular mimicry of the CCR5 co-receptor.In fact,Tat binds the V3 loop of the HIV Env at the same residues binding the CCR5,allowing the generation and stabilization of complexes presenting cryptic and/or transiently exposed Env epitopes.These are crucial for inducing cross-clade neutralizing antibodies. In addition , R5 viruses are the major virus phenotype transmitted to healthy individuals.The goal of VIAV will be fulfilled through the achievement of specific objectives which, in turn, are the focus of specific workpackages: 1.Characterization of the Tat/V3loop com plex through the combined application of bioinformatics tools, NMR studies and microcalorimetry measurements 2.Generation,chemical-physical,immunological and biological characterization of Tat/Env complexes and their formulation for in vitro and in vivo s tudies 3.Evaluation of the safety and immunogenicity of different Tat/Env complex-based vaccine formulations in small animal models 4.Characterization of the specificity of the antibody responses generated in immunized animals 5.Characterization of virus-s pecific and cross-clade neutralizing activity of antibodies generated in immunized animals. The achievement of VIAV objectives will be implemented through a rigorous management of the scientific, business and administrative activities by the Steering Commi ttee and by the Project Coordinator. VIAV is linked to the AIDS Vaccine Integrated Project (AVIP),recently awarded by the EU Commission, for future product development and clinical testing

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ISTITUTO SUPERIORE DI SANITÀ

Address

Viale Regina Elena 299
Rome

Italy

Administrative Contact

Flavia FERRANTELLI (Dr)

Participants (8)

Sort alphabetically

Expand all

CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLOPROTEINE PARAMAGNETICHE

Italy

DIATHEVA S.R.L.

Italy

LUNDS UNIVERSITET

Sweden

TERRAMATICA CONSULTING SRL

Italy

UNIVERSITETET I BERGEN

Norway

UNIVERSITY OF FERRARRA

Italy

UNIVERSITY OF PADUA

Italy

UNIVERSITY OF URBINO "CARLO BO"

Italy

Project information

Grant agreement ID: 12188

  • Start date

    1 January 2005

  • End date

    31 December 2007

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 1 090 000

  • EU contribution

    € 1 000 000

Coordinated by:

ISTITUTO SUPERIORE DI SANITÀ

Italy